MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1212/wnl.0000000000210211

Медицинская библиотека · Neurology · 2024

Comparison of Plasma p-tau217 and [18F]FDG-PET for Identifying Alzheimer Disease in People With Early-Onset or Atypical Dementia.

Quispialaya Kely Monica, Therriault Joseph, Aliaga Antonio, Benedet Andrea L, Ashton Nicholas J, Karikari Thomas, Cassa Macedo Arthur, Rahmouni Nesrine, Tissot Cécile, Fernandez Arias Jaime, Wang Yi-Ting Tina, Trudel Lydia, Hosseini Seyyed Ali, Matsudaira Takashi, Chan Tevy, Pascoal Tharick, Gilfix Brian, Vitali Paolo, Zimmer Eduardo R, Provost Karine, Soucy Jean-Paul, Gauthier Serge, Zetterberg Henrik, Jean-Claude Bertrand J, Blennow Kaj, Rosa-Neto Pedro

СтатьяСравнительное исследованиеПеревод пока не подготовлен

Аннотация

BACKGROUND AND

OBJECTIVES

To compare the diagnostic performance of an immunoassay for plasma concentrations of phosphorylated tau (p-tau) 217 with visual assessments of fluorine-18 fluorodeoxyglucose [18F]FDG-PET in individuals who meet appropriate use criteria for Alzheimer dementia (AD) biomarker assessments.

METHODS

We performed a retrospective analysis of individuals with early-onset (age <65 years at onset) and/or atypical dementia (features other than memory at onset), who were evaluated at a tertiary care memory clinic. All participants underwent measurements of CSF biomarkers (Aβ42, p-tau181, and total tau levels), as well as [18F]FDG-PET scans, amyloid-PET scans, and plasma p-tau217 quantifications. To determine whether the [18F]FDG-PET images were compatible with AD, images were visually rated by 2 nuclear medicine experts. Using a contingency analysis, we evaluated the accuracy of [18F]FDG-PET scan interpretation and plasma p-tau217 for an AD biomarker profile in CSF and for amyloid-PET positivity.

RESULTS

A total of 81 individuals with early onset and/or atypical dementia were included in this study (mean age = 65 years; 48/81 female (59%). Both [18F]FDG-PET and plasma p-tau217 showed high levels of agreement with reference standard AD biomarkers ([18F]FDG-PET area under the curve [AUC]: 71%; plasma p-tau217 AUC: 81%). Although both biomarkers had similar specificity for AD [18F]FDG-PET: 70%, CI: 0.56-0.81; plasma p-tau217: 70%, CI: 0.56-0.81), plasma p-tau217 had higher sensitivity for AD (plasma p-tau217: 97%, CI: 0.85-0.99 vs [18F]FDG-PET: 73%, CI: 0.57-0.85) (p = 0.01). Overall accuracy was also higher for plasma p-tau217 (AUC = 84%, CI: 0.75-0.93 vs 72%, CI: 0.60-0.83 of [18F]FDG-PET) (p = 0.02). The same pattern of results was observed when using amyloid-PET as the reference standard.

DISCUSSION: Our study provides evidence that plasma p-tau217 has strong discriminative accuracy for AD among patients with early-onset and/or atypical dementia assessed in specialized settings. Future work should replicate these findings in secondary care settings.

Для цитирования: Quispialaya Kely Monica, Therriault Joseph, Aliaga Antonio, Benedet Andrea L, Ashton Nicholas J, Karikari Thomas, Cassa Macedo Arthur, Rahmouni Nesrine, Tissot Cécile, Fernandez Arias Jaime, Wang Yi-Ting Tina, Trudel Lydia, Hosseini Seyyed Ali, Matsudaira Takashi, Chan Tevy, Pascoal Tharick, Gilfix Brian, Vitali Paolo, Zimmer Eduardo R, Provost Karine, Soucy Jean-Paul, Gauthier Serge, Zetterberg Henrik, Jean-Claude Bertrand J, Blennow Kaj, Rosa-Neto Pedro. Comparison of Plasma p-tau217 and [18F]FDG-PET for Identifying Alzheimer Disease in People With Early-Onset or Atypical Dementia.. Neurology. 2024. DOI: 10.1212/wnl.0000000000210211.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.